Ryan Kelly is the Interim Chief Executive Officer and Senior Director of Supply Chain Security & Brand Protection at Rx-360, an international, member-driven pharmaceutical supply chain consortium focused on patient safety, quality, and supply chain integrity. In this role, he leads cross-industry initiatives spanning joint audits, supply chain security, and quality oversight, and works closely with regulators, manufacturers, suppliers, and logistics partners to strengthen risk management across global supply networks.

Ryan Kelly, Rx360, shares expert strategies for mapping, auditing, and protecting pharmaceutical supply chains to ensure global patient safety.

Ryan Kelly's Tips for Drug Supply Chain Protection

how third-party audits and integrated quality-supply chain strategies protect pharma supply chains and patient safety.

, Ryan Kelly, interim CEO and senior director of Supply Chain Security and Brand Protection, Rx360, discusses how pharmaceutical organizations can better protect their supply chains and, ultimately, ensure patient safety.

Kelly narrows in on this piece of advice: know where your product is at every stage of its journey. As Kelly puts it, "Make sure you understand every single product and its entire end-to-end flow."

This means tracking inventory from raw materials and APIs through in-process manufacturing, packaging, final labeling, and delivery to the customer. Kelly notes that many organizations lack full visibility into where their physical product actually resides at any given moment.

Beyond mapping, Kelly emphasizes the importance of rigorous auditing. Companies should evaluate their suppliers and service providers not only against expected practices, but against every possible risk within those partners' operations. Digitizing this process, he adds, makes the effort significantly more effective.

Kelly also speaks on how Rx360 synthesizes standards from the FDA, Health Canada, and other global regulatory bodies into a unified framework covering good manufacturing, distribution, and clinical practices. Rather than defaulting to the lowest common regulatory denominator.